Assured Investment Management’s Neurocrine Biosciences NBIX Stock Holding History

Assured Investment Management’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-63,570	Closed	-$5.6M	–	557
2019 Q1	$5.6M	Buy	63,570 +48,240	+315%	+$4.03M	0.06%	136
2018 Q4	$1.09M	Buy	+15,330	New	+$1.47M	0.03%	435
2017 Q1	–	Sell	-22,022	Closed	-$852K	–	686
2016 Q4	$852K	Buy	22,022 +21,017	+2,091%	+$951K	0.02%	352
2016 Q3	$51K	Sell	1,005 -4,896	-83%	-$244K	﹤0.01%	577
2016 Q2	$268K	Buy	+5,901	New	+$272K	0.01%	473
2016 Q1	–	Sell	-1,995	Closed	-$113K	–	687
2015 Q4	$113K	Sell	1,995 -9,821	-83%	-$499K	﹤0.01%	544
2015 Q3	$470K	Buy	+11,816	New	+$571K	0.01%	365

Other funds holding NBIX

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Assured Investment Management's NBIX Position: Q2 2019 in Review

Assured Investment Management sold out of Neurocrine Biosciences (NBIX) in Q2 2019, closing a stake of 63,570 shares — an estimated $5.6M sold.

Assured Investment Management first reported a position in NBIX in Q3 2015 and held it in 7 quarters. The position peaked at $5.6M in Q1 2019. 302 funds tracked by Wall St. Rank hold NBIX as of Q2 2019.

Assured Investment Management reported no remaining Neurocrine Biosciences position as of Q2 2019 after selling out during the quarter.
Assured Investment Management sold 63,570 Neurocrine Biosciences shares in Q2 2019, an estimated $5.6M.
Assured Investment Management first reported a position in Neurocrine Biosciences in Q3 2015 and held it in 7 quarters.
Assured Investment Management's Neurocrine Biosciences position peaked at $5.6M in Q1 2019.
302 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2019.

Based on Assured Investment Management's 13F filing for Q2 2019, filed 14 Aug 2019.